Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
India
/
Pharmaceuticals & Biotech
Create a narrative
Cipla
NSEI:CIPLA Community
1
Narratives
written by author
0
Comments
on narratives written by author
39
Fair Values set
on narratives written by author
Create a narrative
Cipla
Popular
Undervalued
Overvalued
Cipla
WA
Analyst Price Target
Consensus Narrative from 37 Analysts
Investments And Launches Of Generic Advair Will Expand US Market Presence
Key Takeaways Strategic investments and a diversified product portfolio position Cipla for sustained growth in the U.S., EMEU, and One Africa markets. Focus on launching high-value assets and digital health initiatives could increase revenue and profit margins in North America and India.
View narrative
₹1.65k
FV
10.4% undervalued
intrinsic discount
8.59%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
23 days ago
author updated this narrative
Your Valuation for
CIPLA
Cipla
Your Fair Value
₹
Current Price
₹1.48k
21.7% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
396b
2015
2018
2021
2024
2025
2027
2030
Revenue ₹396.3b
Earnings ₹74.0b
Advanced
Set as Fair Value